Cargando…

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

BACKGROUND AND AIMS: Pioglitazone targets multiple pathogenic pathways involved in the development of cardiovascular diseases (CVD). The aim of this systematic review and meta-analysis is to assess the effects of pioglitazone treatment on the secondary prevention of CVD. METHODS: Randomized-controll...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Jong, Marit, van der Worp, H. Bart, van der Graaf, Yolanda, Visseren, Frank L. J., Westerink, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644073/ https://www.ncbi.nlm.nih.gov/pubmed/29037211 http://dx.doi.org/10.1186/s12933-017-0617-4

Ejemplares similares

The influence of baseline risk on the relation between HbA1c and risk for new cardiovascular events and mortality in patients with type 2 diabetes and symptomatic cardiovascular disease
por: Bots, Sophie H., et al.
Publicado: (2016)

Impact of a Patient’s Baseline Risk on the Relative Benefit and Harm of a Preventive Treatment Strategy: Applying Trial Results in Clinical Decision Making
por: de Vries, Tamar I., et al.
Publicado: (2021)

Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all‐cause mortality: Findings from the SMART cohort
por: Sharif, Shahnam, et al.
Publicado: (2019)

The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study
por: van’t Klooster, Cilie C, et al.
Publicado: (2019)

Prediction of Lifetime and 10-Year Risk of Cancer in Individual Patients With Established Cardiovascular Disease
por: van ’t Klooster, Cilie C., et al.
Publicado: (2020)

Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes
por: Sharif, Shahnam, et al.
Publicado: (2021)

Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?
por: Berkelmans, Gijs F. N., et al.
Publicado: (2020)

Development of a clinical decision tool to reduce diagnostic testing for primary aldosteronism in patients with difficult-to-control hypertension
por: van Kleef, Monique E. A. M., et al.
Publicado: (2020)

Added value of cardiovascular calcifications for prediction of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease
por: van ’t Klooster, Cilie C., et al.
Publicado: (2021)

Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study
por: Verhagen, Sandra N, et al.
Publicado: (2011)

Comment on Vistisen et al. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901–907
por: Østergaard, Helena Bleken, et al.
Publicado: (2021)

Multifocal cardiovascular calcification in patients with established cardiovascular disease; prevalence, risk factors, and relation with recurrent cardiovascular disease
por: van 't Klooster, Cilie C., et al.
Publicado: (2020)

Pharmacological and non-pharmacological interventions to influence adipose tissue function
por: Westerink, Jan, et al.
Publicado: (2011)

The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease
por: Schrover, Ilse M, et al.
Publicado: (2018)

Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients
por: Stam-Slob, Manon C., et al.
Publicado: (2016)

Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular disease
por: Kranendonk, Mariëtte EG, et al.
Publicado: (2014)

Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis
por: van der Pol, Karel H., et al.
Publicado: (2021)

Lifestyle changes and kidney function: A 10‐year follow‐up study in patients with manifest cardiovascular disease
por: Østergaard, Helena Bleken, et al.
Publicado: (2022)

Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study
por: Østergaard, Helena Bleken, et al.
Publicado: (2022)

Cardiovascular risk factor treatment targets and renal complications in high risk vascular patients: a cohort study
por: Selvarajah, Sharmini, et al.
Publicado: (2011)

The relationship between walking speed and changes in cardiovascular risk factors during a 12-day walking tour to Santiago de Compostela: a cohort study
por: Bemelmans, Remy H H, et al.
Publicado: (2012)

Screen-detected abnormal ankle brachial index: A risk indicator for future cardiovascular morbidity and mortality in patients with manifest cardiovascular disease
por: Jagt, Vivianne L., et al.
Publicado: (2022)

The daily 10 kcal expenditure deficit: a before-and-after study on low-cost interventions in the work environment
por: Dorresteijn, Johannes A N, et al.
Publicado: (2013)

Novel Biomarkers to Improve the Prediction of Cardiovascular Event Risk in Type 2 Diabetes Mellitus
por: van der Leeuw, Joep, et al.
Publicado: (2016)

Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives
por: Jaspers, Nicole E M, et al.
Publicado: (2018)

Fever worsens outcomes in animal models of ischaemic stroke: A systematic review and meta-analysis
por: de Jonge, Jeroen C, et al.
Publicado: (2018)

Arterial stiffness as a risk factor for cardiovascular events and all‐cause mortality in people with Type 2 diabetes
por: Sharif, S., et al.
Publicado: (2019)

External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease
por: Smidt, Lisanne C. A., et al.
Publicado: (2021)

Modifiable risk factors in adults with and without prior cardiovascular disease: findings from the Indonesian National Basic Health Research
por: Arsyad, Dian Sidik, et al.
Publicado: (2022)

Cost‐Effectiveness of Intensifying Lipid‐Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients
por: Stam‐Slob, Manon C., et al.
Publicado: (2017)

The efficacy and safety of pioglitazone in psoriasis vulgaris: A meta-analysis of randomized controlled trials
por: Chen, Pengfei, et al.
Publicado: (2020)

Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus
por: de Vries, T. I., et al.
Publicado: (2018)

Preventive ceftriaxone in patients at high risk of stroke-associated pneumonia. A post-hoc analysis of the PASS trial
por: Sluis, Wouter M., et al.
Publicado: (2022)

Risk Stratification in Patients with Ischemic Stroke and Residual Cardiovascular Risk with Current Secondary Prevention
por: Gynnild, Mari Nordbø, et al.
Publicado: (2021)

Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care
por: de Beus, Esther, et al.
Publicado: (2017)

Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study
por: Chen, Yu-Hsin, et al.
Publicado: (2016)

Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort study
por: de Vries, Tamar Irene, et al.
Publicado: (2021)

Screening for type 2 diabetes in a high-risk population: study design and feasibility of a population-based randomized controlled trial
por: Klijs, Bart, et al.
Publicado: (2012)

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity
por: Jacques, Vincent, et al.
Publicado: (2021)

Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk
por: Zou, Cong, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kd935s5e6d787qvfqn8gtnagrk